Search results for " Pharmaceutic"

showing 10 items of 865 documents

Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.

2017

Here, nano into micro formulations (NiMs) of tobramycin for the treatment of Pseudomonas aeruginosa airway infections in cystic fibrosis (CF) are described. NiMs were produced by spray drying a solution containing polymers or sugars and a nanometric polyanion–tobramcyin complex (PTC), able to achieve a prolonged antibiotic release. NiMs properties were compared to TOBIPodhaler(Novartis), the only one commercially available dry powder inhalatory formulation based on porous microparticles. Produced NiMs showed adequate characteristics for pulmonary administration, as spherical shape, micrometric size, and high cytocompatibility toward human bronchial epithelial cells. Contrarily to TOBIPodhal…

Tobramycin Cystic Fibrosis Artificial Mucus (CF-AM) αβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) ion pair complex nano into micro strategy Pseudomonas aeruginosa infections biofilmPolymers and PlasticsCystic FibrosisPolymersChemistry PharmaceuticalBioengineeringBronchi02 engineering and technologymedicine.disease_causeCystic fibrosisMicrobiologyBiomaterials03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNano-Materials ChemistrymedicineTobramycinHumansPseudomonas InfectionsParticle SizeRespiratory Tract InfectionsCells CulturedDrug CarriersPseudomonas aeruginosaChemistryBiofilmDry Powder InhalersEpithelial Cells021001 nanoscience & nanotechnologyAntimicrobialmedicine.diseaseMucusPolyelectrolytesAnti-Bacterial Agents030228 respiratory systemSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSpray dryingBiofilmsDelayed-Action PreparationsPseudomonas aeruginosaTobramycinNanoparticles0210 nano-technologymedicine.drugBiomacromolecules
researchProduct

Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.

2004

1. A study performed > 10 years ago and case reports published recently suggest that triclabendazole is effective for the treatment of patients with fascioliasis. 2. To confirm the efficacy of a human formulation of triclabendazole, we enrolled 165 patients into the present study and divided the subjects into two groups: (i) those who had fascioliasis, as evidenced by the presence of ova in their stools; and (ii) patients with clinical and laboratory data suggesting fascioliasis. 3. Patients were randomly allocated to receive 10 mg/kg, p.o., triclabendazole for 1, 2 or 3 days (single-, double- and triple-dose groups, respectively). Medical history and physical and laboratory examinations we…

Toxic hepatitisAdultMalemedicine.medical_specialtyCure rateFascioliasisAdolescentPhysiologyChemistry PharmaceuticalGastroenterologylaw.inventionFecesRandomized controlled triallawOral administrationPhysiology (medical)Internal medicineMedicineHumansMedical historyIn patientChildTriclabendazoleAgedPharmacologyAnthelminticsDose-Response Relationship Drugbusiness.industryMiddle AgedSurgeryTriclabendazoleTreatment OutcomeHuman fascioliasisImmunoglobulin GBenzimidazolesFemalemedicine.symptombusinessmedicine.drugClinical and experimental pharmacologyphysiology
researchProduct

Suppression of intestinal microbiota-dependent production of pro-atherogenic trimethylamine N-oxide by shifting L-carnitine microbial degradation.

2014

Abstract Aims Trimethylamine-N-oxide (TMAO) is produced in host liver from trimethylamine (TMA). TMAO and TMA share common dietary quaternary amine precursors, carnitine and choline, which are metabolized by the intestinal microbiota. TMAO recently has been linked to the pathogenesis of atherosclerosis and severity of cardiovascular diseases. We examined the effects of anti-atherosclerotic compound meldonium, an aza-analogue of carnitine bioprecursor gamma-butyrobetaine (GBB), on the availability of TMA and TMAO. Main methods Wistar rats received L-carnitine, GBB or choline alone or in combination with meldonium. Plasma, urine and rat small intestine perfusate samples were assayed for L-car…

TrimethylamineTrimethylamine N-oxideBacterial growthBiologyGeneral Biochemistry Genetics and Molecular BiologyStatistics NonparametricCholinechemistry.chemical_compoundMethylaminesBetaineTandem Mass SpectrometryCarnitineBlood plasmamedicineCholineAnimalsCarnitineGeneral Pharmacology Toxicology and PharmaceuticsRats WistarChromatography High Pressure LiquidMeldoniumCarbon IsotopesMicrobiotaGeneral MedicineBiosynthetic PathwaysRatsBetaineGastrointestinal TractBiochemistrychemistrymedicine.drugMethylhydrazinesLife sciences
researchProduct

Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity

2018

Abstract Pyrrolizinones represent an interesting class of compounds with varied degrees of structural complexity and pharmacological activity. Among these, 9H-pyrido[2,3-b]pyrrolizin-9-one, tripentone analogs, recently reported by us, showed significant antiproliferative activity against human tumor cell lines, inducing apoptosis and not affecting viability of Caco-2 differentiated in normal intestinal-like cells. Considering their interesting biological activity, their 5H-pyrido[3,2-b]pyrrolizin-5-one analogs were efficiently synthesized in good to excellent yields (61–91%). All tripentone derivatives were tested to assess their cytotoxicity against two human tumor cell lines, HCT-116 (hum…

TripentonesPyridinesAntineoplastic AgentsApoptosisAntiproliferative activity5H-pyrido[3; 2-b]pyrrolizin-5-ones; Antiproliferative activity; Antitumor; Apoptosis; Tripentones; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry010402 general chemistry01 natural sciencesStructure-Activity Relationship2-b]pyrrolizin-5-onesCell Line TumorNeoplasmsDrug DiscoverymedicineHumansCytotoxic T cellPyrrolesCytotoxicityMitosisIC505H-pyrido[32-b]pyrrolizin-5-onePharmacology010405 organic chemistryChemistryDrug Discovery3003 Pharmaceutical ScienceOrganic Chemistry5H-pyrido[3ApoptosiTripentoneCancerBiological activityAntitumorGeneral MedicineHCT116 Cellsmedicine.disease0104 chemical sciencesCell cultureApoptosisMCF-7 CellsCancer researchCaco-2 CellsDrug Screening Assays AntitumorEuropean Journal of Medicinal Chemistry
researchProduct

Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense.

2020

Starting from the reversible rhodesain inhibitors 1 a-c, which have Ki values towards the target protease in the low-micromolar range, we have designed a series of peptidomimetics, 2 a-g, that contain a benzodiazepine scaffold as a β-turn mimetic; they are characterized by a specific peptide sequence for the inhibition of rhodesain. Considering that irreversible inhibition is strongly desirable in the case of a parasitic target, a vinyl ester moiety acting as Michael-acceptor was introduced as the warhead; this portion was functionalized in order to evaluate the size of corresponding enzyme pocket that could accommodate this substituent. With this investigation, we identified an irreversibl…

Trypanosoma brucei rhodesiensehuman African trypanosomiasiStereochemistryPeptidomimeticmedicine.medical_treatmentSubstituentAntiprotozoal AgentsTrypanosoma bruceiCysteine Proteinase Inhibitors01 natural sciencesBiochemistrychemistry.chemical_compoundBenzodiazepinesStructure-Activity RelationshipDrug DevelopmentParasitic Sensitivity TestsDrug DiscoverymedicineMoietyTrypanosoma bruceiGeneral Pharmacology Toxicology and PharmaceuticsPeptide sequencePharmacologyrhodesainProteasebiologyDose-Response Relationship DrugMolecular Structure010405 organic chemistryOrganic ChemistryTrypanosoma brucei rhodesiensebenzodiazepine scaffoldbiology.organism_classificationpeptidomimetic0104 chemical sciences010404 medicinal & biomolecular chemistryCysteine EndopeptidaseschemistryMolecular MedicinePeptidomimeticsMichael acceptorLead compoundChemMedChem
researchProduct

Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antipr…

2014

Novel papain-family cathepsin L-like cysteine protease inhibitors endowed with antitrypanosomal and antimalarial activity were developed, through an optimization study of previously developed inhibitors. In the present work, we studied the structure-activity relationships of these derivatives, with the aim to develop new analogues with a simplified and more synthetically accessible structure and with improved antiparasitic activity. The structure of the model compounds was significantly simplified by modifying or even eliminating the side chain appended at the C3 atom of the benzodiazepine scaffold. In addition, a simple methylene spacer of appropriate length was inserted between the benzod…

Trypanosomamedicine.drug_classPeptidomimeticStereochemistryAntiparasiticCell SurvivalCathepsin LAntiprotozoal AgentsCysteine Proteinase InhibitorsBiochemistryCathepsin BCell LineCathepsin Lchemistry.chemical_compoundBenzodiazepinesMiceStructure-Activity RelationshipDrug DiscoverymedicineMoietyAnimalsGeneral Pharmacology Toxicology and PharmaceuticsPharmacologyCathepsinbiologyOrganic ChemistryCombinatorial chemistryCysteine proteasePapainantiprotozoal agents; inhibitors; Malaria; Peptidomimetics; structure-activity relationshipsCysteine EndopeptidaseschemistryAntiprotozoalbiology.proteinMolecular MedicineProtein BindingChemMedChem
researchProduct

Protective effect of trehalose-loaded liposomes against UVB-induced photodamage in human keratinocytes

2014

Trehalose, a naturally occurring non-reducing disaccharide, is known to act as a major protein stabilizer that can reduce ultraviolet B (UVB)-induced corneal damage when topically applied to the eye. However, due to the low skin permeability of trehalose, which makes the development of topical formulations difficult, its use as a skin photoprotective agent has been limited. Previous findings demonstrated that liposomes may significantly improve the intracellular delivery of trehalose. Therefore, the present study aimed to assess the protective effects of trehalose-loaded liposomes against UVB-induced photodamage using the immortalized human keratinocyte cell line, HaCaT. The effects were al…

Ultraviolet radiationKeratinocytesCienciaPyrimidine dimerBiologyPharmacologyPhotoprotective agentGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundmedicineGeneral Pharmacology Toxicology and PharmaceuticsCiencias médicasLiposomeintegumentary systemGeneral NeurosciencePiel - InvestigaciónTrehaloseArticlesGeneral Medicinemedicine.diseaseTrehaloseProtein carbonylationCyclobutane pyrimidine dimersHaCaTchemistryApoptosisPhotoprotectionImmunology8-hydroxy-2'-deoxyguanosineSkin cancerBiomedical Reports
researchProduct

Recent progress in understanding the non-neuronal cholinergic system in humans.

2007

Urinary Tract Physiological PhenomenaMusculoskeletal Physiological PhenomenaRespiratory Physiological PhenomenaChemistryMusculoskeletal Physiological PhenomenaGeneral MedicineGeneral Biochemistry Genetics and Molecular BiologyAcetylcholineImmune SystemCholinergic systemRespiratory Physiological PhenomenaAnimalsHumansReceptors CholinergicUrinary Tract Physiological PhenomenaGeneral Pharmacology Toxicology and PharmaceuticsNeuroscienceLife sciences
researchProduct

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

Vascular Endothelial Growth Factor ACancer ResearchLung NeoplasmsAmbrisentanOncology and CarcinogenesisDrug ResistanceBiological AvailabilityAntineoplastic AgentsDrug resistanceCell LineMiceErlotinib HydrochlorideGefitinibIn vivomedicineAnimalsHumansOncology & CarcinogenesisNon-Small-Cell LungProtein Kinase InhibitorsLungCancerTumor microenvironmentTumorEndothelin-1business.industryCarcinomaLung CancerCancerEvaluation of treatments and therapeutic interventionsGefitinibmedicine.diseaseEndothelin 1Xenograft Model Antitumor AssaysErbB ReceptorsOncologyVasoconstriction5.1 Pharmaceuticals6.1 PharmaceuticalsCancer cellMutationCancer researchNeoplasmDevelopment of treatments and therapeutic interventionsbusinessmedicine.drug
researchProduct

Comparative Study of Different Methods for the Prediction of Drug–Polymer Solubility

2015

In this study, a comparison of different methods to predict drug-polymer solubility was carried out on binary systems consisting of five model drugs (paracetamol, chloramphenicol, celecoxib, indomethacin, and felodipine) and polyvinylpyrrolidone/vinyl acetate copolymers (PVP/VA) of different monomer weight ratios. The drug-polymer solubility at 25 °C was predicted using the Flory-Huggins model, from data obtained at elevated temperature using thermal analysis methods based on the recrystallization of a supersaturated amorphous solid dispersion and two variations of the melting point depression method. These predictions were compared with the solubility in the low molecular weight liquid ana…

Vinyl CompoundsRecrystallization (geology)PolymersChemistry PharmaceuticalIndomethacinAnalytical chemistryPharmaceutical ScienceFlory–Huggins solution theorychemistry.chemical_compoundDrug StabilityDrug DiscoveryVinyl acetatemedicineSolubilityThermal analysisAcetaminophenSupersaturationChromatographyCalorimetry Differential ScanningFelodipinePolyvinylpyrrolidonePovidonePyrrolidinonesChloramphenicolSolubilitychemistryCelecoxibThermodynamicsMolecular MedicineCrystallizationMelting-point depressionmedicine.drugMolecular Pharmaceutics
researchProduct